Literature DB >> 8968348

Injured erythrocytes release adenosine deaminase into the circulation.

E K Jackson1, Z Mi, M T Koehler, J A Carcillo, W A Herzer.   

Abstract

The purpose of this study was to test the hypothesis that circulating red blood cells (RBCs) release adenosine deaminase (ADA) when injured. This hypothesis was evaluated in rats using dimethyl sulfoxide (DMSO) to damage RBCs. Boluses and infusions of DMSO caused a reduction in urinary adenosine and a concomitant hemoglobinuria, and the ability of DMSO to reduce urinary adenosine was blocked by pretreatment with the ADA inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine. Infusions of DMSO also significantly enhanced ADA activity in urine and plasma. Dimethylsulfone, an analog of DMSO that does not affect RBCs, did not cause hemoglobinuria and did not affect urinary adenosine. High concentrations of DMSO did not affect adenosine metabolism in rat kidneys perfused without RBCs, and DMSO did not decrease urinary adenosine in rats rendered severely anemic (hematocrit < 15%) by replacing whole blood with plasma. However, DMSO did decrease urinary adenosine in rats without a spleen, a major source of adenosine deaminase apart from circulating RBCs. DMSO reduced renal interstitial levels of adenosine and attenuated bradycardic responses to exogenous adenosine, and these effects were prevented by erythro-9-(2-hydroxy-3-nonyl)adenine. These results indicate that circulating damaged RBCs release significant amounts of ADA, a process that may predispose to vasoocclusive events.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968348

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Extracellular 3',5'-cAMP-adenosine pathway inhibits glomerular mesangial cell growth.

Authors:  Raghvendra K Dubey; Marinella Rosselli; Delbert G Gillespie; Zaichuan Mi; Edwin K Jackson
Journal:  J Pharmacol Exp Ther       Date:  2010-03-01       Impact factor: 4.030

2.  Hemoglobinuria in the Early Poststem-Cell-Transplant Period: Risk Factors and Association with Outcomes.

Authors:  Panagiotis Kompotiatis; Sandhya Manohar; Hassan B Alkhateeb; William J Hogan; Karl A Nath; Nelson Leung
Journal:  Kidney360       Date:  2021-08-25

3.  Nonresolving inflammation in gp91phox-/- mice, a model of human chronic granulomatous disease, has lower adenosine and cyclic adenosine 5'-monophosphate.

Authors:  Ravindra Rajakariar; Justine Newson; Edwin K Jackson; Precilla Sawmynaden; Andrew Smith; Farooq Rahman; Muhammad M Yaqoob; Derek W Gilroy
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

4.  Failure to upregulate the adenosine2A receptor-epoxyeicosatrienoic acid pathway contributes to the development of hypertension in Dahl salt-sensitive rats.

Authors:  Elvira L Liclican; John C McGiff; John R Falck; Mairéad A Carroll
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-01

Review 5.  Extracellular nucleotide and nucleoside signaling in vascular and blood disease.

Authors:  Marco Idzko; Davide Ferrari; Ann-Kathrin Riegel; Holger K Eltzschig
Journal:  Blood       Date:  2014-07-07       Impact factor: 22.113

6.  Characterization of the N6-etheno-bridge method to assess extracellular metabolism of adenine nucleotides: detection of a possible role for purine nucleoside phosphorylase in adenosine metabolism.

Authors:  Edwin K Jackson; Delbert G Gillespie; Dongmei Cheng; Zaichuan Mi; Elizabeth V Menshikova
Journal:  Purinergic Signal       Date:  2020-05-04       Impact factor: 3.765

7.  Novel Guidewire Design and Coating for Continuous Delivery of Adenosine During Interventional Procedures.

Authors:  Mervyn B Forman; Erik C Brewer; Zachary R Brown; Elizabeth V Menshikova; Anthony M Lowman; Edwin K Jackson
Journal:  J Am Heart Assoc       Date:  2021-01-26       Impact factor: 5.501

8.  Experimental intravascular hemolysis induces hemodynamic and pathological pulmonary hypertension: association with accelerated purine metabolism.

Authors:  Victor P Bilan; Frank Schneider; Enrico M Novelli; Eric E Kelley; Sruti Shiva; Mark T Gladwin; Edwin K Jackson; Stevan P Tofovic
Journal:  Pulm Circ       Date:  2018-07-13       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.